Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Short-term Investments (2022 - 2023)

OptimizeRx (OPRX) has disclosed Short-term Investments for 2 consecutive years, with $53.6 million as the latest value for Q3 2023.

  • Quarterly Short-term Investments rose 43.11% to $53.6 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $53.6 million through Sep 2023, up 43.11% year-over-year, with the annual reading at $55.9 million for FY2022, N/A changed from the prior year.
  • Short-term Investments hit $53.6 million in Q3 2023 for OptimizeRx, up from $52.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $57.3 million in Q1 2023 to a low of $37.5 million in Q3 2022.